As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Zynerba Pharmaceuticals

  • Thursday's Range: $4.64-$6.01
  • 52-Week Range: $4.64-$43.00
  • Thursday's Volume: 98,000
  • Three-Month Average Volume: 67,044

Zynerba Pharmaceuticals  (ZYNE) , a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. This stock closed up 18.8% to $5.93 in Thursday's trading session.

From a technical perspective, Zynerba Pharmaceuticals exploded sharply higher on Thursday and displayed relative strength versus the overall market weakness with above-average volume. This strong spike to the upside is coming after shares of Zynerba Pharmaceuticals printed a new 52-week low at $4.64 on Thursday and then managed to close well off that level. This stock is now quickly trending within range of triggering a near-term breakout trade. That trade will trigger if shares of Zynerba Pharmaceuticals manages to take out some near-term overhead resistance levels at $6.56 to $6.72 a share with high volume.

Traders should now look for long-biased trades in Zynerba Pharmaceuticals as long as it's trending above $5.50 or $5 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 67,044 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 20-day moving average of $7.15 to $7.50, or even $8 a share.

Fluidigm

  • Thursday's Range: $5.37-$6.14
  • 52-Week Range: $4.84-$46.38
  • Thursday's Volume: 1.23 million
  • Three-Month Average Volume: 533,708

 

Fluidigm  (FLDM)  creates, manufactures, and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics. This stock traded up 5.6% to $6.02 in Thursday's trading session.

From a technical perspective, Fluidigm ripped sharply higher on Thursday and counter-trended versus the overall market weakness right above some near-term support at $5.09 a share with strong upside volume flows. This high-volume rip to the upside is now starting to push shares of Fluidigm within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out Thursday's intraday high of $6.14 a share and then once it clears more key resistance at $6.50 to its 20-day moving average of $6.61 a share with high volume.

Traders should now look for long-biased trades in Fluidigm as long as it's trending above Thursday's intraday low of $5.37 or above more near-term support at $5.09 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 533,708 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.54 to its 50-day moving average of $8.70 a share.

Halozyme Therapeutics

  • Thursday's Range: $6.96-$7.62
  • 52-Week Range: $6.96-$25.25
  • Thursday's Volume: 2.02 million
  • Three-Month Average Volume: 1.42 million

Halozyme Therapeutics  (HALO) , a biotechnology company, researches, develops, and commercializes human enzymes. This stock traded up 3.6% to $7.43 in Thursday's trading session.

From a technical perspective, Halozyme Therapeutics jumped notably higher on Thursday and displayed some relative strength versus the overall market weakness with strong upside volume flows. This stock has been downtrending badly over the last month and change, with shares collapsing off its high of $17.78 to its new 52-week low of $6.96 a share hit on Thursday. During that downtrend, shares of Halozyme Therapeutics have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock rebound off its new 52-week low on Thursday with big volume and closed well above its intraday low. This rebound is now quickly pushing shares of Halozyme Therapeutics within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out Thursday's intraday high of $7.62 a share and then above more resistance at $7.88 a share with high volume.

Traders should now look for long-biased trades in Halozyme Therapeutics as long as it's trending above its new 52-week low of $6.96 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 1.42 million shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 20-day moving average of $8.77 to $8.89, or even $9.06 to $9.50 a share.

Natera

  • Thursday's Range: $6.70-$7.11
  • 52-Week Range: $6.52-$23.24
  • Thursday's Volume: 252,000
  • Three-Month Average Volume: 241,268

Natera  (NTRA) , a genetic testing company, develops and commercializes non-invasive methods for analyzing DNA in the U.S. and Europe. This stock traded up 1.9% to $6.98 in Thursday's trading session.

From a technical perspective, Natera trended modestly higher on Thursday right above its new 52-week low of $6.52 a share with above-average volume. This stock has been bucking the overall market weakness the last few trading sessions with some decent upside volume flows. This spike to the upside on Thursday is now quickly pushing shares of Natera within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $7.11 to $7.22 a share with high volume.

Traders should now look for long-biased trades in Natera as long as it's trending above its new 52-week low of $6.52 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 241,268 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8 to its 20-day moving average of $8.12, or even $8.50 to $9 a share.

Calithera Biosciences

  • Thursday's Range: $4.32-$4.83
  • 52-Week Range: $4.31-$22.00
  • Thursday's Volume: 89,000
  • Three-Month Average Volume: 191,853

Calithera Biosciences  (CALA) , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the U.S. This stock traded up 7.1% to $4.79 in Thursday's trading session.

From a technical perspective, Calithera Biosciences ripped sharply higher on Thursday and displayed some relative strength versus the overall market weakness with lighter-than-average volume. This stock spiked to the upside right off some previous support from last August at $4.31 a share. This rip to the upside is now quickly pushing shares of Calithera Biosciences within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $4.88 to $4.92 a share and then over its 20-day moving average of $5.01 a share with high volume.

Traders should now look for long-biased trades in Calithera Biosciences as long as it's trending above that major support area at $4.31 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 191,853 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out is next major overhead resistance levels at $5.16 to $5.20, or even $5.50 to $6 a share.

InVivo Therapeutics

  • Thursday's Range: $3.54-$3.84
  • 52-Week Range: $3.50-$19.68
  • Thursday's Volume: 138,000
  • Three-Month Average Volume: 322,803

InVivo Therapeutics  (NVIV) , a research and clinical-stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injury. This stock traded up 3.8% to $3.80 in Thursday's trading session.

From a technical perspective, InVivo Therapeutics trended notably higher on Thursday and counter-trended versus the overall market weakness right off its new 52-week low of $3.50 a share with lighter-than-average volume. This stock has been downtrending badly for the last three months, with shares collapsing off its high of $11.80 to its new 52-week low of $3.50 a share. During that downtrend, shares of InVivo Therapeutics have been making mostly lower highs and lower lows, which is bearish technical price action. That said, this stock bounced has started to bounce off that $3.50 low, and it's now quickly moving within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out Thursday's intraday high of $3.84 a share and then once it clears some more key resistance levels at $3.94 to $4 a share with high volume.

Traders should now look for long-biased trades in InVivo Therapeutics as long as it's trending above its new 52-week low of $3.50 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 322,803 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 20-day moving average of $4.24 to $4.50, or even $4.58 to $4.79 a share.

XBiotech

  • Thursday's Range: $7.21-$7.84
  • 52-Week Range: $6.36-$32.50
  • Thursday's Volume: 31,000
  • Three-Month Average Volume: 240,221

 

XBiotech  (XBIT) , a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various different diseases. This stock traded up 3.2% to $7.66 in Thursday's trading session.

From a technical perspective, XBiotech spiked notably higher right off some near-term support at $7.09 a share and briefly trended back above its 20-day moving average of $7.70 a share with lighter-than-average volume. This display of relative strength versus the overall market weakness on Thursday is now quickly pushing shares of XBiotech within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will hit if shares of XBiotech manages to take out some near-term overhead resistance levels at $7.99 to $8.06 a share with high volume.

Traders should now look for long-biased trades in XBiotech as long as it's trending above Thursday's intraday low of $7.21 a share or above more near-term support at $7.09 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 240,221 shares. If that breakout gets started soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8.50 to $8.67, or even its 50-day moving average of $9.25 a share.

Rexahn Pharmaceuticals

  • Thursday's Range: $0.34-$0.37
  • 52-Week Range: $0.26-$0.85
  • Thursday's Volume: 282,000
  • Three-Month Average Volume: 441,237

Rexahn Pharmaceuticals  (RNN) , a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer and other medical needs. This stock traded up 10.1% to 37 cents per share in Thursday's trading session.

From a technical perspective, Rexahn Pharmaceuticals surged sharply higher on Thursday right off its 20-day moving average of 34 cents per share and right into its 50-day moving average of 37 cents per share with lighter-than-average volume. This counter-trend spike to the upside is now quickly pushing shares of Rexahn Pharmaceuticals within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at 38 cents to 40 cents per share and then above more resistance at 41 cents to 42 cents per share with high volume.

Traders should now look for long-biased trades in Rexahn Pharmaceuticals as long as it's trending above its 20-day moving average of 34 cents per share or above more near-term support at 32 cents per share and then once it sustains a move or close above those breakout levels with volume that registers near or above 441,237 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at 45 cents to 48 cents per share, or even 52 cents to 55 cents per share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

More from Opinion

Microsoft Pops on Strong Earnings and Guidance: 8 Key Takeaways

Microsoft Pops on Strong Earnings and Guidance: 8 Key Takeaways

Bitcoin Is Up, but Traditional Investors Remain Skeptical

Bitcoin Is Up, but Traditional Investors Remain Skeptical

EBay's Soft Guidance Doesn't Reflect Well on its Attempts to Fight Off Amazon

EBay's Soft Guidance Doesn't Reflect Well on its Attempts to Fight Off Amazon

4 Key Takeaways for Apple, Nvidia and Others From TSMC's Earnings Report

4 Key Takeaways for Apple, Nvidia and Others From TSMC's Earnings Report

3 Things to Watch When Microsoft Reports Earnings

3 Things to Watch When Microsoft Reports Earnings